Loren K. Mell
University of California, San Diego
CancerInternal medicineRadiologySurgeryOncologyRandomized controlled trialMedical physicsHazard ratioHead and neck cancerChemotherapyCervical cancerChemoradiotherapyBone marrowPopulationIntensity-modulated radiation therapyNuclear medicineConfidence intervalRadiation therapyClinical trialMedicine
321Publications
52H-index
7,504Citations
Publications 321
Newest
#2T.J. NelsonH-Index: 1
Last. Brent S. RoseH-Index: 19
view all 9 authors...
Source
#1Whitney Sumner (UCSD: University of California, San Diego)H-Index: 1
#2Loren K. Mell (UCSD: University of California, San Diego)H-Index: 52
Source
#1Casey W. Williamson (UCSD: University of California, San Diego)H-Index: 8
#2Igor SirákH-Index: 13
Last. Michael T. McHale (UCSD: University of California, San Diego)H-Index: 21
view all 19 authors...
Purpose null To test effects of positron emission tomography (PET)-based bone marrow-sparing (BMS) image-guided intensity modulated radiation therapy (IMRT) on efficacy and toxicity for patients with locoregionally advanced cervical cancer. null Methods and materials null In an international phase II/III trial, patients with stage IB-IVA cervical carcinoma were treated with either PET-based BMS-IG-IMRT (PET-BMS-IMRT group) or standard image-guided IMRT (IMRT group), with concurrent cisplatin (40...
Source
#1Karoline Kallis (UCSD: University of California, San Diego)H-Index: 1
#2Jyoti Mayadev (UCSD: University of California, San Diego)H-Index: 15
Last. John P. Einck (UCSD: University of California, San Diego)H-Index: 16
view all 13 authors...
Abstract null null PURPOSE null The use of interstitial needles, combined with intracavitary applicators, enables customized dose distributions and is beneficial for complex cases, but increases procedure time. Overall, applicator selection is not standardized and depends on physician expertise and preference. The purpose of this study is to determine whether dose prediction models can guide needle supplementation decision-making for cervical cancer. null null null MATERIALS AND METHODS null Int...
Source
#1Casey W. Williamson (UCSD: University of California, San Diego)H-Index: 8
Last. Loren K. Mell (UCSD: University of California, San Diego)H-Index: 52
view all 4 authors...
The standard of care for the definitive treatment of locoregionally advanced cervical cancer is external beam radiation therapy (EBRT) with concurrent chemotherapy followed by a brachytherapy boost. Historically, EBRT was delivered via a two-dimensional technique based primarily on bony landmarks. This gave way to three-dimensional conformal radiation therapy, which allows for dose calculation and adjustment based on individual tumour and patient anatomy. Further technological advances have esta...
Source
#1Casey W. Williamson (UCSD: University of California, San Diego)H-Index: 8
#2Loren K. Mell (UCSD: University of California, San Diego)H-Index: 52
Source
#1Christopher S Babu (Cornell University)
#2Loren K. Mell (UCSD: University of California, San Diego)H-Index: 52
Last. Kaveh Zakeri (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 9
view all 4 authors...
Access to randomized clinical trial (RCT) protocols is necessary for the interpretation and reproducibility of the study results, but protocol availability has been lacking. We determined the prevalence of protocol availability for all published cancer RCTs in January 2020. We found that only 36.1% (48/133) of RCTs had an accessible protocol and only 11.3% of RCTs (15/133) had a publicly accessible protocol that was not behind a paywall. Only 18.0% (24/133) of RCTs were published in conjunction ...
Source
#2Jonathan Harris (American College of Radiology)H-Index: 28
The anti-PD1 monoclonal antibody pembrolizumab improves survival in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Patients with locoregional, pathologically high-risk HNSCC recur frequently despite adjuvant cisplatin–radiation therapy (CRT). Targeting PD1 may reverse immunosuppression induced by HNSCC and CRT. We conducted a phase I trial with an expansion cohort (n = 20) to determine the recommended phase II schedule (RP2S) for adding fixed-dose pembrolizumab to standard a...
Source
#1Abhishek Kumar (UCSD: University of California, San Diego)H-Index: 46
#1Abhishek Kumar (UCSD: University of California, San Diego)H-Index: 9
Source
Source